Big Pharma has put a Houston pharmacy squarely in the crosshairs of its quest to weed out copycat versions of wildly popular diabetes and weight loss drugs. Eli Lilly, the maker of the diabetes drug Mounjaro and weight loss drug Zepbound,

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA announced that a shortage of Mounjaro and Zepbound had been resolved.

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a diabetes treatment since 2019. It's an orally available version of semaglutide, which is the same active ingredient in Ozempic and Wegovy.